|
|
|
| Effects of Metformin Combined with Liraglutide on Islet α and β Cells, Cytokines and Cellular Immune Function in Patients with T2DM |
| LIU Ling-lin, ZHANG Chen-chen, XIONG Wei |
| Department of Geriatric Diseases, Southwest Hospital, the Army Medical University, Chongqing 400038 |
|
|
|
|
Abstract 【Objective】To investigate the effects of metformin combined with liraglutide on islet α and β cells, cytokines and cellular immune function in patients with type 2 diabetes mellitus (T2DM).【Methods】From April 2016 to April 2017, 102 patients with T2DM were selected. According to the random table method, the patients were divided into observation group and control group with 51 cases in each group. The observation group was treated with metformin and liraglutide, the control group was treated only by metformin. The course of treatment was 12 weeks in both groups. Before and after treatment, the changes of FPG, 2hPG, HbA1c, HOMA-IR, HOMA-β, fasting glucagon (FGlg), IL-6, IGF-1, TNF-α, CD3+and CD4+CD4+/CD8+were compared between the two groups.【Results】After treatment, FPG, 2h PG and HbA1c in both groups were significantly lower than those before treatment (P<0.05). After treatment, HOMA-IR and FGlg decreased and HOMA-β increased in both groups (P<0.05). After treatment, HOMA-IR and FGlg in the observation group were lower than those in the control group, but HOMA-β was higher than that in the control group (P<0.05). After treatment, the level of IL-6, IGF-1, TNF-αdecreased in both groups (P<0.05). The level of IL-6, IGF-1 and TNF-αin the observation group was lower than that of the control group (P<0.05). CD4 and CD4/CD8 of CD8 were increased in both groups after treatment (P<0.05). The levels of CD3+, CD4+and CD4+/CD8+in the observation group were higher than those in the control group (t=10.8227、5.9040、7.1660, P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).【Conclusion】The curative effect of metformin combined with Lilaru peptide on T2DM patients is significant. It can improve the islets alpha and beta cells, cytokines and cellular immune functions of the patients, and is worthy of clinical application.
|
|
Received: 20 September 2017
|
|
|
|
|
|
[1] Inzucchi SE,Bergenstal RM,Buse JB,et al.Management of hyperglycemia in type 2 diabetes,2015:a patient-centered approach:update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes[J].Diabetes Care,2015,38(1):140-149.
[2] Udell JA.Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment:observations from the SAVOR-TIMI 53 Trial [J].Diabetes Care,2015,38(4):696-705.
[3] Tikkanen I,Narko K,Zeller C,et al.Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension[J].Diabetes Care,2015,38(3):420.
[4] Zannad F.Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE:a multicentre,randomised,double-blind trial.[J].Lancet,2015,385(9982):2067-2076.
[5] 王晓茜,鲁丹,唐莉,等.利拉鲁肽治疗2型糖尿病的研究进展[J].现代生物医学进展,2015,15(19):3777-3778.
[6] 宋效成,李赐林,黄斌,等.利拉鲁肽治疗2型糖尿病的疗效[J].实用临床医学,2015,16(6):12.
[7] 许美玲,仇雨轩,于俊杰,等.利拉鲁肽治疗2型糖尿病的临床研究进展[J].现代生物医学进展,2015,15(3):598-600.
[8] 蒙光义,王冬晓,庞家莲,等.利拉鲁肽联合二甲双胍治疗2型糖尿病的疗效观察[J].中国药房,2015,13(5):658-661.
[9] 王小娟.2型糖尿病和糖调节异常患者胰岛α、β细胞功能的变化[J].中国现代医学杂志,2017,27(9):108-112.
[10] 胡帼英,黄威鸳.参芪扶正注射液对糖尿病患者T淋巴细胞亚群及氧化应激水平的影响[J].中国生化药物杂志,2016,36(11):151-153.
[11] 贾晓利,周广朋,陈树.老年2型糖尿病患者细胞免疫功能改变的相关性研究[J].四川医学,2009,30(9):1378-1381.
[12] 董晓蕾,阮萍,雍军光,等.空腹血糖水平对2型糖尿病患者红细胞变形和免疫功能的影响[J].中国糖尿病杂志,2015,14(9):827-831.
[13] 李培育,高宏伟,董天崴,等.2型糖尿病伴抑郁症患者外周血Th1/Th2/Th17相关细胞因子水平变化[J].中国老年学,2015,35(16):4559-4561.
[14] 苏冬月.2型糖尿病患者脂联素基因多态性与细胞因子相关性分析[J].现代预防医学,2015,42(2):320-322.
[15] 张黎明,高凌.炎症细胞因子在2型糖尿病发病机制中的研究进展[J].重庆医学,2016,45(8):1113-1116. |
|
|
|
2018, Vol. 35 
